Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Scher, H. I.
Beer, T. M.
Higano, C. S.
Taplin, M.
Efstathiou, E.
Anand, A.
Hung, D.
Hirmand, M.
Fleisher, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Univ Washington, SCCA, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Medivation Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Zhang, Hongyong
    Wang, Yu
    Ghosh, Paramita
    Lara, Primo N., Jr.
    Pasquinelli, Patricia
    Beckett, Laurel
    White, Ralph W. deVere
    Pan, Chong-Xian
    CANCER RESEARCH, 2010, 70
  • [32] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Pan, C.
    Ghosh, P.
    Suga, J. M.
    Paequinelli, P.
    Beckett, L.
    White, R. Deere
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Castration-resistant prostate cancer (CRPC) [Kastrationsrefraktäres prostatakarzinom (CRPC)]
    Loidl W.
    Luger F.
    Roosen A.
    Der Urologe, 2014, 53 (3): : 391 - 401
  • [34] A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher P.
    Parikh, Mamta
    White, Ralph de Vere
    Dall'era, Marc
    Liu, Chengfei
    Robles, Daniel
    Gao, Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
    Chandrasekar, Thenappan
    Yang, Joy C.
    Gao, Allen C.
    Evans, Christopher P.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 365 - 380
  • [36] Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC)
    Suarez, Cristina
    Morales-Barrera, Rafael
    Ramos, Victor
    Nunez, Isaac
    Valverde, Claudia
    Planas, Jacques
    Morote, Juan
    Maldonado, Xavier
    Carles, Joan
    BJU INTERNATIONAL, 2014, 113 (03) : 367 - 375
  • [37] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study.
    Shamash, J.
    Jacob, J.
    Powles, T.
    Agrawal, S.
    Mutsvangwa, K.
    Saunders, N.
    Wilson, P.
    Stebbing, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC).
    Morris, Michael J.
    Bruce, Justine Yang
    Reyno, Leonard M.
    Anand, Banmeet
    Hartford, Alan
    Jelaca-Maxwell, Kathy
    Lackey, Jacqueline
    Eisenberger, Mario A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Clinical Activity and Tolerability of Enzalutamide ( MDV3100) in Patients With Metastatic, Castration- Resistant Prostate Cancer Who Progress After Docetaxel and Abiraterone Treatment
    Badrising, Sushil
    van der Noort, Vincent
    van Oort, Inge M.
    van den Berg, H. Pieter
    Los, Maartje
    Hamberg, Paul
    Coenen, Jules L.
    van den Eertwegh, Alfons J. M.
    de Jong, Igle J.
    Kerver, Emile D.
    van Tinteren, Harm
    Bergman, Andries M.
    CANCER, 2014, 120 (07) : 968 - 975
12345